Immunescience Industries Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 535.59%
- Profit Growth -327.56%
- Ebitda -327.56%
- Net Worth -10.96%
- Total Assets -5.69%
About Immunescience Industries
Immunescience Industries Private Limited (IIPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 September 2020 (Four years and five months 23 days old ). Its registered office is in Gandhi Nagar, Gujarat, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sunita Sharma and Avish Sharma serve as directors at the Company.
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999GJ2020PTC116112
- Company No.
116112
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Sep 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Immunescience Industries?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunita Sharma  | Director | 03-Sep-2020 | Current |
| Avish Sharma | Director | 03-Sep-2020 | Current |
Financial Performance of Immunescience Industries.
Immunescience Industries Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 535.59% increase. The company also saw a substantial fall in profitability, with a 327.56% decrease in profit. The company's net worth observed a substantial decline by a decrease of 10.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immunescience Industries?
In 2022, Immunescience Industries had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Immunescience Industries?
Immunescience Industries has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immunescience Industries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunescience Industries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.